应用68Ga-PSMA-11 PET/CT评估转移性去势抵抗性前列腺癌患者的治疗反应:EAU/EANM推荐在临床实践中的应用
该研究回顾性纳入18例开始一线新型内分泌药物治疗的转移性去势抵抗性前列腺癌患者,于基线、治疗第4周和第12周行68Ga-PSMA-11 PET/CT,并在基线和第12周行传统影像。结果显示68Ga-PSMA-11 PET/CT可评估16/18例(89%)的治疗反应,传统影像可评估11/18例(61%);第4周与第12周PET/CT结果高度一致(κ=0.74),但2/16例(13%)因闪现现象在第4周被误判为进展。结论认为68Ga-PSMA-11 PET/CT体积评估可改善新型内分泌药物治疗患者的反应评估,但第4周早期评估需谨慎。
要点
- 68Ga-PSMA-11 PET/CT在16/18例(89%)中可评估治疗反应,传统影像仅11/18例(61%)可评估。
- 第4周与第12周68Ga-PSMA-11 PET/CT反应评估结果高度一致(κ=0.74)。
- 2/16例(13%)因闪现现象在第4周被误判为进展,第12周该现象消失。
核心结论
- 68Ga-PSMA-11 PET/CT体积评估可改善新型内分泌药物治疗的转移性去势抵抗性前列腺癌患者的反应评估。
- 第4周早期反应评估因闪现现象需谨慎对待,第4周与第12周68Ga-PSMA-11 PET/CT反应评估结果高度一致。
- 上述发现需进一步研究以区分第4周的进展与闪现现象,并帮助理解治疗耐药。
研究设计与样本
- 回顾性纳入18例开始新型内分泌药物治疗的转移性去势抵抗性前列腺癌患者。
- 患者在治疗前(基线)、第4周和第12周行68Ga-PSMA-11 PET/CT,并在基线和第12周行传统影像(骨显像、CT)。
- 对PET/CT图像进行最大SUV、平均SUV和PSMA配体阳性病灶总数的定量分析。
- 根据68Ga-PSMA-11 PET/CT、前列腺特异性抗原和传统影像标准将患者分类为无进展性疾病或进展性疾病。
主要发现
- 68Ga-PSMA-11 PET/CT可评估16/18例(89%)的治疗反应,传统影像可评估11/18例(61%)。
- 第12周经68Ga-PSMA-11 PET/CT分类为进展性疾病的16例中有5例在第4周已符合进展标准。
- 第4周与第12周68Ga-PSMA-11 PET/CT结果高度一致(κ=0.74)。
- 2/16例(13%)因PSMA PET/CT上的闪现现象在第4周被误判为进展性疾病,该现象在第12周消失。
关键数值与推荐
- 采用欧洲泌尿外科学会(EAU)和欧洲核医学协会(EANM)推荐进行反应评估。
- 68Ga-PSMA-11 PET/CT可评估率16/18例(89%),传统影像可评估率11/18例(61%)。
- 第4周与第12周68Ga-PSMA-11 PET/CT结果一致性κ=0.74。
- 第4周误判为进展性疾病的比例为2/16例(13%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性研究。
- 样本量为18例。
- 作者指出第4周早期反应评估因闪现现象需谨慎对待。
- 作者指出上述发现需进一步研究以区分第4周的进展与闪现现象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For patients with metastatic castration-resistant prostate cancer (mCRPC), no reliable biomarkers for predicting therapeutic response or assisting in treatment selection and sequencing are currently available. Using the recent European Association of Urology and European Association of Nuclear Medicine recommendations, we aimed to compare response assessment between prostate-specific membrane antigen (PSMA) PET/CT and conventional imaging in mCRPC patients starting first-line treatment with a novel hormonal agent (NHA) and to perform a sequential comparative analysis of PSMA PET/CT-derived parameters after 4 and 12 wk of therapy. Methods: Data from 18 mCRPC patients who started NHA treatment and underwent 68Ga-PSMA-11 PET/CT before therapy initiation (baseline), at week 4 (W4), and at week 12 (W12) in addition to conventional imaging (bone scintigraphy, CT) at baseline and W12 were retrospectively included. PET/CT images were quantitatively analyzed for maximum and mean SUV and total PSMA ligand-positive lesions. Comparative analysis of PET/CT-derived parameters was performed, and patients were classified as having nonprogressive disease or progressive disease (PD) according to 68Ga-PSMA-11 PET/CT, prostate-specific antigen, and conventional imaging criteria. Results: Treatment response was evaluable by 68Ga-PSMA-11 PET/CT in 16 of 18 patients (89%) and by conventional imaging in 11 of 18 patients (61%). Five of 16 patients classified as having PD by 68Ga-PSMA-11 PET/CT at W12 had already met progression criteria at W4, and substantial agreement was observed between W4 and W12 (κ, 0.74) 68Ga-PSMA-11 PET/CT results. Nonetheless, 2 of 16 patients (13%) were incorrectly classified as having PD because of a flare phenomenon on PSMA PET/CT that disappeared at W12. Conclusion: Volumetric assessments of 68Ga-PSMA-11 PET/CT imaging can improve response evaluation in NHA-treated patients with mCRPC. Although early response assessments at W4 need to be approached with caution because of flare, 68Ga-PSMA-11 PET/CT imaging at W4 and W12 revealed substantial agreement in therapy response assessments; these findings warrant further investigation to distinguish PD from flare at W4 and help improve the understanding of resistance to therapy.
引用
- Denis CS, Cousin F, Laere B, et al. Using 68Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical Practice. J Nucl Med. 2022. PMID: 35450960. doi:10.2967/jnumed.121.263611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。